瘧疾疫苗市場：依疫苗類型、病原體、年齡、通路、最終用戶和地區分類。

預計2026年，瘧疾疫苗市場規模為7億美元，2033年將達16.366億美元。預計從2026年到2033年，其複合年成長率將達到12.9%。

瘧疾是一種危及生命的疾病，由寄生蟲感染引起，透過受感染的阿諾菲勒斯蚊叮咬傳播給人類。目前瘧疾預防和控制策略，例如使用經殺蟲劑處理的蚊帳、噴灑殺蟲劑和抗瘧疾藥，已被證明不足以控制疾病的傳播。因此，瘧疾疫苗已成為降低瘧疾流行地區發病率和死亡率的迫切且必要的公共衛生工具。由於疫苗無需大規模醫療基礎設施即可提供長期免疫力，因此它們是實現瘧疾根除目標的一種經濟有效且永續的解決方案。

市場動態

全球瘧疾疫苗市場的主要驅動力是全球整體瘧疾負擔沉重，尤其是在非洲國家；世界衛生組織為瘧疾疫苗研發提供的大量資金；以及疫苗作為一項關鍵公共衛生措施的日益普及。然而，由於瘧疾原蟲複雜的生命週期以及對保護性免疫反應缺乏全面了解，有效瘧疾疫苗的研發仍面臨許多技術挑戰，這些挑戰持續限制市場潛力。同時，疫苗學、免疫學和病原體基因組學的不斷進步為開發新的疫苗設計方法和抗原靶點創造了機會。其他機會包括擴大疫苗生產能力，並透過世界衛生組織（世衛組織）、良好技術衛生環境規劃署（PATH）、瘧疾疫苗計劃（PATH MVI）和各國免疫規劃的協調努力，確保疫苗在上市後能夠及時送達瘧疾流行地區。

本次調查的主要特點

本報告對全球瘧疾疫苗市場進行了詳細分析，顯示了預測期（2026-2033 年）的市場規模和複合年成長率（%），以 2025 年為基準年。

本報告指出了各個細分市場的潛在商機，並說明了該市場中具有吸引力的投資提案矩陣。

此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略。

本研究根據以下參數對全球瘧疾疫苗市場的主要參與者進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。

本研究涵蓋的主要公司包括葛蘭素史克公司、Sanaria公司、諾貝爾製藥公司、Sumaya Biotech公司、GenVec公司、默克公司、輝瑞公司、強生公司、Bharat Biotech公司、印度血清研究所、武田製藥公司、Novavax公司、Inovio製藥公司、Vaxart公司和BioNTech SE SE 公司。

本報告中的見解將使各公司的行銷負責人和經營團隊能夠就未來的產品發布、產品改進、市場擴張和行銷策略做出明智的決策。

全球瘧疾疫苗市場報告的目標受群眾外包括該行業的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。

透過分析全球瘧疾疫苗市場中使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

目錄

第1章：研究目標與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要

第3章：市場動態、監管與趨勢分析

• 市場動態
• 促進因素
• 抑制因子
• 機會
• 影響分析
• 主要進展
• 監管趨勢
• 產品上市及核准
• PEST分析
• 波特的分析
• 併購情景
• 產業趨勢

第4章 全球瘧疾疫苗市場：依疫苗類型分類，2021-2033年

• 紅血球疫苗接種前
• 紅血球疫苗
• 多重抗原疫苗

第5章 全球瘧疾疫苗市場：依病原體分類，2021-2033年

• 瘧疾原蟲
• 間日瘧原蟲瘧疾原蟲
• 按蚊屬

第6章 全球瘧疾疫苗市場：依年齡層別分類，2021-2033年

• 兒童
• 成人

第7章 全球瘧疾疫苗市場：依通路分類，2021-2033年

• 民眾
• 私人的

第8章 全球瘧疾疫苗市場：依最終用戶分類，2021-2033年

• 醫院
• 專科診所
• 區域醫療中心
• 居家醫療

第9章 全球瘧疾疫苗市場：依地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲國家
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太國家
• 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東國家
• 非洲
  • 南非
  • 北非
  • 中非

第10章 競爭格局

• GlaxoSmithKline plc
• Sanaria Inc.
• Nobelpharma Co.
• Sumaya Biotech
• GenVec
• Merck & Co., Inc.
• Pfizer Inc.
• Johnson & Johnson
• Bharat Biotech
• Serum Institute of India
• Takeda Pharmaceutical Company
• Novavax, Inc.
• Inovio Pharmaceuticals
• Vaxart, Inc.
• BioNTech SE

第11章 分析師建議

• 機會分析
• 分析師意見
• Coherent Opportunity Map

第12章 參考文獻與調查方法

• 參考
• 調查方法
• 關於本公司

Malaria Vaccines Market is estimated to be valued at USD 700.0 Mn in 2026 and is expected to reach USD 1,636.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 12.9% from 2026 to 2033.

Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected Anopheles mosquitoes. The currently available strategies for malaria prevention and control such as insecticide treated nets, spraying of insecticides and antimalarial drugs are proving insufficient to curb the spread of the disease. This makes malaria vaccines an urgent and vital public health tool to reduce malaria morbidity and mortality in endemic regions. Vaccines can provide long lasting immunity without requiring large healthcare infrastructure, thereby offering a cost-effective and sustainable solution towards malaria elimination goals.

Market Dynamics

The global malaria vaccines market is primarily driven by the high disease burden of malaria worldwide, especially in African countries, massive funding for malaria vaccine development from global health organizations and growing acceptance of vaccines as an important public health intervention. However, technical challenges in developing an effective malaria vaccine owing to the complex life cycle of parasite Plasmodium and lack of comprehensive understanding of protective immune responses continue to restrain market potential. Meanwhile, ongoing advancements in vaccinology, immunology, and pathogen genomics have created opportunities for the development of novel vaccine design approaches and antigen targets. Further opportunities lie in expanding manufacturing capacity and ensuring successful uptake of malaria vaccines, once available, in malaria endemic populations through coordinated efforts of World Health Organization (WHO), Program for Appropriate Technology in Health, Malaria Vaccine Initiative (PATH MVI), and government immunization programs.

Key Features of the Study

This report provides in-depth analysis of the global malaria vaccines market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year.

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.

It profiles key players in the global malaria vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.

Key companies covered as a part of this study include GlaxoSmithKline plc, Sanaria Inc., Nobelpharma Co., Sumaya Biotech, GenVec, Merck & Co., Inc., Pfizer Inc., Johnson & Johnson, Bharat Biotech, Serum Institute of India, Takeda Pharmaceutical Company, Novavax, Inc., Inovio Pharmaceuticals, Vaxart, Inc., and BioNTech SE.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.

The global malaria vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global malaria vaccines market.

Market Segmentation

• Vaccine Type Insights (Revenue, USD Mn, 2021 - 2033)
• Pre-Erythrocytic Vaccines
• Erythrocytic Vaccines
• Multi-Antigen Vaccines
• Agent Insights (Revenue, USD Mn, 2021 - 2033)
• Plasmodium Falciparum
• Plasmodium Vivax
• Anopheles Species
• Age Insights (Revenue, USD Mn, 2021 - 2033)
• Pediatric
• Adult
• Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
• Public
• Private
• End Users Insights (Revenue, USD Mn, 2021 - 2033)
• Hospitals
• Specialty Clinics
• Community Health Centers
• Homecare
• Regional Insights (Revenue, USD Mn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
• GlaxoSmithKline plc
• Sanaria Inc.
• Nobelpharma Co.
• Sumaya Biotech
• GenVec
• Merck & Co., Inc.
• Pfizer Inc.
• Johnson & Johnson
• Bharat Biotech
• Serum Institute of India
• Takeda Pharmaceutical Company
• Novavax, Inc.
• Inovio Pharmaceuticals
• Vaxart, Inc.
• BioNTech SE

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Malaria Vaccines Market, By Vaccine Type
  • Global Malaria Vaccines Market, By Agent
  • Global Malaria Vaccines Market, By Age
  • Global Malaria Vaccines Market, By Distribution Channel
  • Global Malaria Vaccines Market, By End Users
  • Global Malaria Vaccines Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Malaria Vaccines Market, By Vaccine Type, 2021 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Pre-Erythrocytic Vaccines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Erythrocytic Vaccines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Multi-Antigen Vaccines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

5. Global Malaria Vaccines Market, By Agent, 2021 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Plasmodium Falciparum
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Plasmodium Vivax
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Anopheles Species
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

6. Global Malaria Vaccines Market, By Age, 2021 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Pediatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Adult
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

7. Global Malaria Vaccines Market, By Distribution Channel, 2021 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Public
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Private
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

8. Global Malaria Vaccines Market, By End Users, 2021 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Specialty Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Community Health Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
• Homecare
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

9. Global Malaria Vaccines Market, By Region, 2021 - 2033, Value (USD Mn)

• Introduction
  • Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Mn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Mn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Vaccine Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Agent, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Age, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By End Users, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Vaccine Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Agent, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Age, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By End Users, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Vaccine Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Agent, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Age, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By End Users, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Vaccine Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Agent, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Age, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By End Users, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Vaccine Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Agent, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Age, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By End Users, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Vaccine Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Agent, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Age, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By End Users, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
    • South Africa
    • North Africa
    • Central Africa

10. Competitive Landscape

• GlaxoSmithKline plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanaria Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Nobelpharma Co.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sumaya Biotech
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GenVec
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bharat Biotech
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Serum Institute of India
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takeda Pharmaceutical Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novavax, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Inovio Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Vaxart, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• BioNTech SE
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us